203787-91-1
203787-91-1 結(jié)構(gòu)式
基本信息
8-水楊酰胺基辛酸鈉
8-(2-羥基苯甲酰氨基)辛酸鈉
8-(2-羥基苯甲酰胺基)辛酸鈉
N-[8-(2-羥苯基)氨基]辛酸鈉
SNAC,8-(2-羥基苯甲酰胺基)辛酸鈉
N-[8-( 2-羥基苯甲?；? 氨基] 辛酸鈉
8-(2-羥基苯甲酰胺基)辛酸鈉SNAC(索馬魯肽關(guān)鍵輔料)
Salcaprozate sodium
Salcaprozate Sodium (SNAC)
sodium 8-(2-hydroxybenzamido)octanoate
sodium,8-[(2-hydroxybenzoyl)amino]octanoate
SODIUM 8-(2-HYDROXYBENZAMIDO)OCTANOATE (SNAC)
SNAC,sodium 8-[(2-hydroxybenzoyl)amino]octanoate
Octanoic acid, 8-[(2-hydroxybenzoyl)amino]-, monosodium salt
物理化學(xué)性質(zhì)
常見問題列表
8-(2-羥基苯甲酰胺基)辛酸鈉，簡稱SNAC，是一種二碳磷酸鹽化合物吸收促進(jìn)劑，用于治療胃腸道疾病，尤其適用于二碳磷酸鹽化合物吸收不良引起的腸胃道疾病。
SNAC (12.5-400 μg/mL; 24 h) has no toxicity to Caco-2 cells, and the survival percentage is above 90% when SNAC is 200 μg/mL.
SNAC (50 and 200 μg/mL) improves the apparent permeability coeffcient (Papp) of RA and SA-B by 2.14-fold and 3.68-fold compared with the Papp of SAs solution.
SNAC improves the oral absorption of both R1 and SAs and enhances bioavailability in rats.
SNAC (2000 mg/kg/d; oral gavage for 13 weeks) related mortality is evident only at the 2000-mg/kg/d level, 20% among males and 50% among females; no clear cause of death is evident.
SNAC (100-1000 mg/kg/d; oral gavage for 13 weeks) induces no mortality in the Wistar rat study at doses up to 1000 mg/kg/d.
| Animal Model: | Sprague-Dawley rats (6-7 weeks) |
| Dosage: | 2000 mg/kg/d |
| Administration: | Oral gavage for 13 weeks |
| Result: | Induced 20% and 50% mortality in males and females at the dose of 2000 mg/kg/d. |
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-114299R | 8-(2-羥基苯甲酰胺基)辛酸鈉 Salcaprozate sodium (Standard) | 203787-91-1 | 25 mg | 370元 |
| 2026/06/05 | HY-114299R | 8-(2-羥基苯甲酰胺基)辛酸鈉 Salcaprozate sodium (Standard) | 203787-91-1 | 50 mg | 560元 |
| 2026/06/05 | HY-114299 | 8-(2-羥基苯甲酰胺基)辛酸鈉 Salcaprozate sodium | 203787-91-1 | 250 mg | 300元 |